Deaths occurred soon after illness onset and mainly occurred in one village, with younger men disproportionately affected.

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

An ongoing investigation into an unexplained illness cluster in the Democratic Republic of the Congo (DRC) Equateur province ...

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

Immunology saw significant contributions from Beyfortus royalties, although Synagis declined year-over-year. Pipeline progress included the U.S. filing for Gamifant in secondary HLH and the ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...

AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...